CA2571055C - Compounds and methods for treating seizure and paroxysmal disorders - Google Patents
Compounds and methods for treating seizure and paroxysmal disorders Download PDFInfo
- Publication number
- CA2571055C CA2571055C CA2571055A CA2571055A CA2571055C CA 2571055 C CA2571055 C CA 2571055C CA 2571055 A CA2571055 A CA 2571055A CA 2571055 A CA2571055 A CA 2571055A CA 2571055 C CA2571055 C CA 2571055C
- Authority
- CA
- Canada
- Prior art keywords
- glucose
- deoxy
- pharmaceutical composition
- epilepsy
- antiglycolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58043604P | 2004-06-17 | 2004-06-17 | |
US60/580,436 | 2004-06-17 | ||
PCT/US2005/021845 WO2006002121A2 (en) | 2004-06-17 | 2005-06-17 | Compounds and methods for treating seizure and paroxysmal disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2571055A1 CA2571055A1 (en) | 2006-01-05 |
CA2571055C true CA2571055C (en) | 2011-11-29 |
Family
ID=35427194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2571055A Active CA2571055C (en) | 2004-06-17 | 2005-06-17 | Compounds and methods for treating seizure and paroxysmal disorders |
Country Status (11)
Country | Link |
---|---|
US (1) | US7795227B2 (ko) |
EP (1) | EP1885379B1 (ko) |
JP (1) | JP2008502705A (ko) |
KR (1) | KR20070034591A (ko) |
CN (1) | CN1972697A (ko) |
AU (2) | AU2005258021B2 (ko) |
BR (1) | BRPI0512161A (ko) |
CA (1) | CA2571055C (ko) |
ES (1) | ES2590259T3 (ko) |
IL (1) | IL179864A0 (ko) |
WO (1) | WO2006002121A2 (ko) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US20090252834A1 (en) * | 2004-05-10 | 2009-10-08 | Michael Griffin Hayek | Compositions comprising glucose anti-metabolites |
ES2590259T3 (es) | 2004-06-17 | 2016-11-21 | Wisconsin Alumni Research Foundation | Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos |
AU2006214489A1 (en) * | 2005-02-14 | 2006-08-24 | Wisconsin Alumni Research Foundation | Metabolic-based methods for modulating gene expression |
US20060217303A1 (en) * | 2005-03-25 | 2006-09-28 | Wisconsin Alumni Research Foundation | Compounds and Methods for Treating Seizure Disorders |
AR052472A1 (es) | 2005-05-31 | 2007-03-21 | Iams Company | Lactobacilos probioticos para felinos |
CA2607949C (en) | 2005-05-31 | 2012-09-25 | Thomas William-Maxwell Boileau | Feline probiotic bifidobacteria |
US20060287253A1 (en) * | 2005-06-17 | 2006-12-21 | Kriegler Steven M | Compounds and methods for treating seizure disorders |
US20080089981A1 (en) * | 2006-10-17 | 2008-04-17 | N.V. Nutricia | Ketogenic diet |
EP2394647A1 (en) | 2006-11-02 | 2011-12-14 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |
AU2008211600B8 (en) * | 2007-02-01 | 2014-02-13 | Mars, Incorporated | Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts |
MX2009008165A (es) * | 2007-02-01 | 2009-08-12 | Iams Company | Metodo para disminuir la inflamacion y el esfuerzo oxidante en mamiferos. |
BRPI0912802A2 (pt) | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US8236768B2 (en) | 2008-10-03 | 2012-08-07 | 3B Pharmaceuticals, Inc. | Topical antiviral formulations |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
EP2600875A1 (en) | 2010-08-04 | 2013-06-12 | Wisconsin Alumni Research Foundation | Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury |
JP5888746B2 (ja) * | 2010-08-24 | 2016-03-22 | 国立大学法人 宮崎大学 | マトリックスメタロプロテアーゼ活性抑制組成物 |
CN106998748A (zh) | 2014-12-08 | 2017-08-01 | 雀巢产品技术援助有限公司 | 用于治疗癫痫的包含中链甘油三酯的组合物和方法 |
US10668041B2 (en) | 2014-12-08 | 2020-06-02 | Societe Des Produits Nestle Sa | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy |
CN106668035A (zh) * | 2017-01-24 | 2017-05-17 | 中南大学湘雅三医院 | 一种抗癫痫药物组合物 |
CN115884766A (zh) * | 2020-05-29 | 2023-03-31 | 睿升公司 | 用于使用中链甘油三酯治疗婴儿痉挛的方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6553994A (en) * | 1993-03-31 | 1994-10-24 | Trustees Of The University Of Pennsylvania, The | Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor |
US5643883A (en) * | 1995-01-19 | 1997-07-01 | Uab Research Foundation | Glucose-6-phosphate uptake inhibitors and novel uses thereof |
US6670330B1 (en) * | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
US6620850B2 (en) | 2001-09-19 | 2003-09-16 | University Of Florida | Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors |
US7145032B2 (en) * | 2002-02-23 | 2006-12-05 | Washington University | Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto |
RU2005125428A (ru) | 2003-01-10 | 2006-03-10 | Тресхолд Фармасьютикалз, Инк. (Us) | Лечение рака 2-деоксиглюкозой |
BRPI0406667A (pt) * | 2003-01-10 | 2005-12-20 | Threshold Pharmaceuticals Inc | Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg |
CN1771043A (zh) | 2003-01-10 | 2006-05-10 | 施瑞修德制药公司 | 利用2-脱氧葡萄糖治疗癌症 |
US20060172953A1 (en) * | 2003-01-17 | 2006-08-03 | Threshold Pharmaceuticals Inc. | Treatment of benign prostatic hyperplasia using energolytic agents |
WO2004064736A2 (en) * | 2003-01-17 | 2004-08-05 | Threshold Pharmaceuticals, Inc. | Treatment of benign prostatic hyperplasia using energolytic agents |
RU2005126042A (ru) | 2003-01-17 | 2006-02-27 | Тресхолд Фармасьютикалз, Инк. (Us) | Лечение доброкачественной гиперплазии простаты |
ES2590259T3 (es) | 2004-06-17 | 2016-11-21 | Wisconsin Alumni Research Foundation | Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos |
US20070292478A1 (en) | 2004-08-30 | 2007-12-20 | Popowski Youri | Medical Implant Provided with Inhibitors of Atp Synthesis |
GB0419990D0 (en) | 2004-09-09 | 2004-10-13 | Suisse Electronique Microtech | Marking articles |
AU2006214489A1 (en) | 2005-02-14 | 2006-08-24 | Wisconsin Alumni Research Foundation | Metabolic-based methods for modulating gene expression |
US20060217303A1 (en) * | 2005-03-25 | 2006-09-28 | Wisconsin Alumni Research Foundation | Compounds and Methods for Treating Seizure Disorders |
US20060287253A1 (en) * | 2005-06-17 | 2006-12-21 | Kriegler Steven M | Compounds and methods for treating seizure disorders |
-
2005
- 2005-06-17 ES ES05787694.8T patent/ES2590259T3/es active Active
- 2005-06-17 AU AU2005258021A patent/AU2005258021B2/en active Active
- 2005-06-17 BR BRPI0512161-2A patent/BRPI0512161A/pt not_active IP Right Cessation
- 2005-06-17 WO PCT/US2005/021845 patent/WO2006002121A2/en active Application Filing
- 2005-06-17 JP JP2007516830A patent/JP2008502705A/ja active Pending
- 2005-06-17 CA CA2571055A patent/CA2571055C/en active Active
- 2005-06-17 US US11/155,200 patent/US7795227B2/en active Active
- 2005-06-17 CN CNA2005800199480A patent/CN1972697A/zh active Pending
- 2005-06-17 KR KR1020077001201A patent/KR20070034591A/ko not_active Application Discontinuation
- 2005-06-17 EP EP05787694.8A patent/EP1885379B1/en active Active
-
2006
- 2006-12-05 IL IL179864A patent/IL179864A0/en unknown
-
2009
- 2009-03-17 AU AU2009201069A patent/AU2009201069A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2008502705A (ja) | 2008-01-31 |
BRPI0512161A (pt) | 2008-02-12 |
AU2005258021A1 (en) | 2006-01-05 |
CN1972697A (zh) | 2007-05-30 |
WO2006002121A3 (en) | 2006-03-02 |
AU2009201069A1 (en) | 2009-04-09 |
EP1885379B1 (en) | 2016-07-20 |
ES2590259T3 (es) | 2016-11-21 |
WO2006002121A2 (en) | 2006-01-05 |
CA2571055A1 (en) | 2006-01-05 |
US20060088517A1 (en) | 2006-04-27 |
KR20070034591A (ko) | 2007-03-28 |
EP1885379A2 (en) | 2008-02-13 |
IL179864A0 (en) | 2007-07-04 |
AU2005258021B2 (en) | 2008-12-18 |
US7795227B2 (en) | 2010-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2571055C (en) | Compounds and methods for treating seizure and paroxysmal disorders | |
US20060287253A1 (en) | Compounds and methods for treating seizure disorders | |
US20060217303A1 (en) | Compounds and Methods for Treating Seizure Disorders | |
JP5690261B2 (ja) | β−ヒドロキシ−β−メチル酪酸および少なくとも1つのアミノ酸を含む組成物および使用法 | |
EP2240170B1 (en) | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage | |
AU2019265002B2 (en) | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener | |
JP7217259B2 (ja) | てんかん及び関連疾患を患う患者の予防及び治療のためのメセンブレノール及び/又はメセンブラノール | |
US20100197610A1 (en) | Fructose 1, 6 bisphosphate - a novel anticonvulsant drug | |
MXPA00012808A (es) | El uso de analogo de acido valproico para tratamiento y prevencion de migrana y enfermedad afectiva. | |
US20070098777A1 (en) | Pharmaceutical or Food Composition for Treatment or Prevention of Brain Edema | |
Mu et al. | NBQX treatment improves mitochondrial function and reduces oxidative events after spinal cord injury | |
EP0217258B1 (en) | The use of choline or choline releasing compounds for reducing the perception of fatigue | |
Zhou et al. | Diazepam monotherapy or diazepam-ketamine dual therapy at different time points terminates seizures and reduces mortality in a status epilepticus animal model | |
JP7570924B2 (ja) | 電位依存性カリウムチャネル開口薬のバイオアベイラビリティー及び曝露を高める方法 | |
RU2664668C1 (ru) | Антиаритмическое лекарственное средство | |
JPH09255579A (ja) | 痴呆治療剤 | |
EP0125900A1 (en) | A pharmaceutical composition for use in treating neurological disease or aging | |
MXPA00011686A (es) | Composicion que comprende acido beta-hidroxi-beta-metilbutirico y al menos un aminoacido y metodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |